ARKG is trading at $52.46, up 3.02%, with the gain appearing to reflect an early-session rebound in genomics and innovation-focused healthcare stocks.
- The rebound follows a 3.69% decline on September 23 and comes despite broader U.S. equity weakness.
- Treasury yields near 5.14%, strong September business activity, and Brent crude above $100 continue to pressure growth valuations; the gain does not appear to reflect a broad market rally.